GRCE — Grace Therapeutics, Cashflow Statement
0.000.00%
Last trade - 00:00- $30.77m
- $19.72m
- 19
- 55
- 86
- 53
Annual cashflow statement for Grace Therapeutics,, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
C2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -25.5 | -19.7 | -9.82 | -42.4 | -12.9 |
| Depreciation | |||||
| Amortisation | |||||
| Non-Cash Items | 3.46 | 10.4 | -4.63 | 26.2 | 1.79 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.22 | -5.95 | -2.79 | 0.181 | -1.28 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -23 | -14.3 | -17.2 | -15.9 | -12.3 |
| Capital Expenditures | -0.319 | -0.069 | 0 | -0.017 | -0.022 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 8.46 | -9.79 | -3.52 | 13.2 | 0.126 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 8.14 | -9.86 | -3.52 | 13.2 | 0.104 |
| Financing Cash Flow Items | 0.007 | -0.143 | 0 | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 13.2 | 59.5 | 0 | 0.304 | 7.36 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -2.63 | 36.7 | -20.6 | -2.46 | -4.87 |